Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab

Saskia Räuber(University of Münster), David Kremer(Heinrich Heine University Düsseldorf), Philipp Albrecht(Heinrich Heine University Düsseldorf), Melanie Korsen(Heinrich Heine University Düsseldorf), Christina B. Schroeter(University of Münster), Niklas Huntemann(University Hospital Münster), Sven G. Meuth(University of Würzburg), Marius Ringelstein(Heinrich Heine University Düsseldorf), Tristan Kölsche(Heinrich Heine University Düsseldorf), Liesa Regner-Nelke(Heinrich Heine University Düsseldorf), Orhan Aktaş(Heinrich Heine University Düsseldorf), Tobias Ruck(University Hospital Münster), Moritz Förster(Heinrich Heine University Düsseldorf), Christopher Nelke(University of Münster), Benedikt Plaack(Heinrich Heine University Düsseldorf), Hans‐Peter Hartung(The University of Sydney), Alice Willison(Düsseldorf University Hospital), Nico Melzer(University of Würzburg), Michael Barnett(The University of Sydney), Kristin S. Golombeck(University of Münster), Leoni Rolfes(University Hospital Münster), Julia Schüller(Heinrich Heine University Düsseldorf)
Frontiers in Immunology
December 23, 2022
Cited by 9


Related Papers